Please login to the form below

Not currently logged in
Email:
Password:

PsiOxus Therapeutics

This page shows the latest PsiOxus Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Bristol-Myers Squibb acquires Cormorant for $520m

Bristol-Myers Squibb acquires Cormorant for $520m

That project will look at the safety and efficacy of enadenotucirev - which is made by PsiOxus Therapeutics in Oxford, UK - in combination with Opdivo for the treatment of a range of

Latest news

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Deal Watch December 2016 Deal Watch December 2016

    995+. PsiOxus Therapeutics (UK). BMS (US). Licence. NG-348: preclinical “ armed” oncolytic virus targeting tumour cells. ... and Bicycle Therapeutics at $1bn, and the Purdue Pharma-Exicure deal, at $790m.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Crescendo Biologics appoints CFO Crescendo Biologics appoints CFO

    She joins from PsiOxus Therapeutics where she served as chief financial officer, and has also held a number of positions at Cytomyx Holdings, OrthoMimetics, and Mission Therapeutics. ... ambitious plans to create a high value pipeline of differentiated

  • Paolo Paoletti named as executive chairman of Kesios Paolo Paoletti named as executive chairman of Kesios

    Imperial Innovations Group has appointed Dr Paolo Paoletti as executive chairman of portfolio company Kesios Therapeutics. ... Paoletti is additionally a non-executive director of PsiOxus Therapeutics, Innovation's sixth largest portfolio company, which

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
COUCH.

WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics